KARRIE INT'L (01050) sets new record in revenue for the fiscal year 2026, with adjusted net profit increasing by 48.3% year-on-year to HK$303 million. The full-year dividend per share is 6 HK cents.
Goldenway International Holdings Limited (01050) announced its annual results for the year ending March 31, 2026. The company achieved a revenue of approximately HK$3.47 billion, representing a 7% year-on-year increase; a net profit of approximately HK$271 million, representing a 32% year-on-year increase; an adjusted net profit of approximately HK$303 million, representing a 48.3% year-on-year increase; basic earnings per share of 13.3 HK cents, representing a 32% year-on-year increase; a final dividend of 4.5 HK cents per share, representing a 50% year-on-year increase, bringing the total dividend per share for the year to 6 HK cents.
KARRIE INT'L (01050) announced its performance for the fiscal year ended March 31, 2026, with revenue of approximately HK$3.47 billion, a year-on-year increase of 7%; net profit of approximately HK$271 million, a year-on-year increase of 32%; adjusted net profit of approximately HK$303 million, a year-on-year increase of 48.3%; basic earnings per share of 13.3 HK cents, a year-on-year increase of 32%; final dividend per share of 4.5 HK cents, a year-on-year increase of 50%, with a total annual dividend per share of 6 HK cents.
During the review year, the group achieved record revenue, mainly driven by the increasing demand for artificial intelligence-related server products, especially ASIC-related server products, which began mass delivery in the second half of the fiscal year and gradually reflected in the group's performance. During the review year, the proportion of artificial intelligence-related products in the group's server chassis increased from approximately 3% in the year ended March 31, 2025 to about 12%, becoming one of the main drivers of the group's revenue and profit growth.
The announcement stated that profit growth was mainly driven by revenue increases, the rise in the proportion of artificial intelligence-related products, optimization of product mix, and operational efficiency improvements, including those at the Thai base. With the gradual increase in the proportion of high value-added structural components, the group's long-term profit capability is expected to further improve.
During the review year, the group made significant progress in the artificial intelligence server supply chain. On one hand, the group has integrated into NVIDIA's server chassis and cabinet component supplier system, working on product development, sample delivery, and mold development for the related new generation platform project. On the other hand, the group also served major cloud service platform customers' demand for ASIC-related servers and cabinet-related products. At the same time, the group actively communicated with various original design manufacturers (ODM), cloud service platform customers (CSP), and related ecosystem customers to seek more opportunities for the introduction of new platforms and products.
To meet the growing demand for artificial intelligence servers, cabinets, and related high-precision structural components, the group continued to optimize its production capacity layout. The Dongguan Fenggang production base in China serves as the group's core technology and main production platform, with complete capabilities in mold, metal stamping, CNC machining, injection molding, surface treatment, assembly, quality inspection, and logistics. The Chonburi Amata Industrial Park production base in Thailand is positioned as a supplementary production platform, mainly to support customer regional delivery arrangements and enhance supply chain resilience, helping to strengthen cross-regional delivery flexibility.
Related Articles

HANXBIO-B (03378) spent approximately HKD 629,900 to repurchase 22,800 shares on June 24th.

US Stock Market Move | Oil stocks generally fell, Occidental Petroleum Corporation (OXY.US) dropped more than 2%
Maiwei Bioscience-B (02493): The clinical trial application for 9MW5211 injection has been approved by the National Medical Products Administration.
HANXBIO-B (03378) spent approximately HKD 629,900 to repurchase 22,800 shares on June 24th.

US Stock Market Move | Oil stocks generally fell, Occidental Petroleum Corporation (OXY.US) dropped more than 2%

Maiwei Bioscience-B (02493): The clinical trial application for 9MW5211 injection has been approved by the National Medical Products Administration.
RECOMMEND





